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COMMENTARY
The use of intraoperative lymphatic mapping (IOLM)
and sentinel node biopsy has substantially changed the
treatment of cutaneous melanoma. Ongoing arguments
over elective versus delayed node dissection have ended,
replaced by widespread adoption of IOLM among
melanoma surgeons worldwide. The single biggest
variable affecting success in IOLM is anatomic location.
The lymphatic drainage patterns of the trunk, extremities
and head and neck are all more variable than originally
predicted from cadaver studies. However, the head and
neck presents surgeons with by far the greatest
challenges. The unique attributes of mapping in the
head and neck will challenge an experienced surgical
oncologist who performs IOLM predominantly for
melanomas of the trunk and extremities. The head and
neck is a three-dimensional (3D) anatomic area inter-
twined with multiple nerves, cosmetic features, and
boundaries. The `̀ shine-through'' problem limits the
surgeon's efforts to use preoperative lymphoscintigraphy
to identify sentinel nodes that overlie radioactive
injection sites. Combine the anatomic complexity with
the fact that the average surgical oncologist sees few
cases of head and neck melanoma, and the result is a
learning curve that can be slow and sometimes painful.
Conversely, the experienced head and neck surgeon
rarely has a high volume of melanoma mapping cases,
and cannot leverage the experience that surgical
oncologists derive from performing sentinel node
biopsies below the clavicle.
Put these technical complexities and turf issues
together, and it is no surprise that the acceptance of
IOLM for melanoma has been slowest in the head and
neck. Meanwhile, controversies abound about indica-
tions, techniques, and adjunctive therapies to be used for
head and neck melanoma patients. It is in this setting
that Gibbs et al. offer their review of surgical therapy of
head and neck melanoma. The `̀ bottom line'' is that they
present no compelling reasons to believe the surgical
treatment of melanomas in this location should be
fundamentally different than elsewhere in the body.
They suggest that IOLM and sentinel node biopsy will
become standard care for head and neck melanoma
patients.
But are we there yet? Head and neck IOLM, like IOLM
for melanomas elsewhere, has improved signi®cant
because of technical improvements in probe design and
a better understanding of the anatomic variations. Our
experience in trunk and extremity melanoma has taught
us to aggressively interrogate multiple drainage sites to
identify node-positive patients or exclude unnecessary
node dissections if only one site is positive. The courage
to attack the parotid in search of sentinel nodes has
allowed surgeons to learn to ®nd individual lymph nodes
within the con®nes of parotid tissue without injury to the
facial nerve. So the answer appears to be yes, the
challenges posed by IOLM in the head and neck can be
handled by the well-trained surgical oncologist or head
and neck surgeon operating as part of an experienced
multidisciplinary team.
There are still, however, many opportunities to
improve IOLM in the head and neck. Prospective clinical
trials will be necessary to de®ne the limits of use. For
example, what is the lower threshold of lesion thickness
for IOLM? Conversely, what are the bene®ts of IOLM in
patients with deep melanomas (>4 mm) where, although
regional failure is a major issue, traditional wisdom
argued against elective node dissection? When micro-
metastases are found within the sentinel nodes, what if
any modi®cations of standard neck dissection procedures
should be made? What adjuvant therapies, such as
radiation and high-dose interferon-a, should be used in
the sentinel node-positive patients? Outside the strictly
medical sphere, we must also wonder whether reimburse-
ment concerns will cloud the picture in the head and neck
if clear data are not available to demonstrate ef®cacy of
IOLM?
We believe that IOLM in the head and neck is a
powerful tool to stage and treat melanoma, with
extraordinarily high degrees of patient acceptance. At
our center, a multidisciplinary approach has allowed
general surgical oncologists and head and neck surgeons
to work side-by-side and bene®t from each others'
expertise. Identical indications are applied to IOLM
for head and neck melanomas as for those occurring
elsewhere on the skin: all patients with melano-
mas 1.00 mm and selected patients with melanomas
<1 mm (speci®cally those with ulceration, extensive
regression or a positive deep margin) are potential
candidates. Likewise, the same approaches to adjuvant
therapy are taken, with sentinel node-positive patients
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evaluated for adjuvant high-dose interferon-a, and
postoperative radiotherapy reserved for patients with
gross extranodal extension or multiple positive nodes
(situations rarely encountered when clinically negative
nodes are found to have microscopic involvement). If the
report by Gibbs et al. serves to motivate surgeons to put
aside preconceived notions and apply consistent surgical
standards to melanomas arising above and below the
clavicle, it will be a valuable contribution indeed.
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